Arcturus and Meiji Seika Pharma Report the EMA’s Positive Opinion of Kostaive for COVID-19
Shots:
- The EMA’s CHMP has granted positive opinion to Kostaive (zepomeran) for active immunization to prevent COVID-19 in subjects of age ≥18yrs.
- The EC’s decision on marketing authorization will follow subsequently
- Kostaive is a self-amplifying mRNA vaccine that codes for the SARS-CoV-2 spike protein to provide active immunization against COVID-19
Ref: Arcturus & Meiji Seika Pharma | Image: Arcturus & Meiji Seika Pharma
Related News:- CSL & Arcturus Therapeutics Receives MHLW Approval for ARCT-154 to Treat COVID in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
